Evidence map›Paper›PMID 32851167›Full record

ArticleScience advances2020

Gliotoxin, identified from a screen of fungal metabolites, disrupts 7SK snRNP, releases P-TEFb, and reverses HIV-1 latency.

Mateusz Stoszko, Abdullah M S Al-Hatmi, Anton Skriba, Michael Roling, Enrico Ne, Raquel Crespo, Yvonne M Mueller, Mohammad Javad Najafzadeh, Joyce Kang, Renata Ptackova and 15 more

Open access · goldAbstract read
In one paragraph

Article in Science advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 26 citations in OpenAlex.

  1. Network Pharmacology-Guided Identification ofInternational journal of molecular sciences · 2026
    Article
  2. Article
  3. Progress in Gliotoxin Research.Molecules (Basel, Switzerland) · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 5 institutions in 7 countries.

Mateusz StoszkoDepartment of Biochemistry, Erasmus MC University Medical Center Rotterdam, PO Box 2040, 3000 CA Rotterdam, Netherlands.ORCID 0000-0002-0629-2492
Abdullah M S Al-HatmiWesterdijk Fungal Biodiversity Institute, Utrecht, Netherlands.ORCID 0000-0002-5206-2647
Anton SkribaInstitute of Microbiology of the Czech Academy of Sciences, Videnska 1083, CZ 14220 Prague 4, Czech Republic.
Michael RolingDepartment of Biochemistry, Erasmus MC University Medical Center Rotterdam, PO Box 2040, 3000 CA Rotterdam, Netherlands.
Enrico NeDepartment of Biochemistry, Erasmus MC University Medical Center Rotterdam, PO Box 2040, 3000 CA Rotterdam, Netherlands.
Raquel CrespoDepartment of Biochemistry, Erasmus MC University Medical Center Rotterdam, PO Box 2040, 3000 CA Rotterdam, Netherlands.
Yvonne M MuellerDepartment of Immunology, Erasmus MC University Medical Center Rotterdam, PO Box 2040, 3000 CA Rotterdam, Netherlands.ORCID 0000-0002-4654-7509
Mohammad Javad NajafzadehWesterdijk Fungal Biodiversity Institute, Utrecht, Netherlands.
Joyce KangKey Laboratory of Environmental Pollution Monitoring/Disease Control, Ministry of Education and Guizhou Talent Base of Microbes and Human Health, School of Basic Medicine, Guizhou Medical University, Guiyang 550025, P. R. China.
Renata PtackovaInstitute of Microbiology of the Czech Academy of Sciences, Videnska 1083, CZ 14220 Prague 4, Czech Republic.ORCID 0000-0001-7705-7871
Elizabeth LeMastersDepartment of Biochemistry, Erasmus MC University Medical Center Rotterdam, PO Box 2040, 3000 CA Rotterdam, Netherlands.
Pritha BiswasDepartment of Biochemistry, Erasmus MC University Medical Center Rotterdam, PO Box 2040, 3000 CA Rotterdam, Netherlands.
Alessia BertoldiDepartment of Biochemistry, Erasmus MC University Medical Center Rotterdam, PO Box 2040, 3000 CA Rotterdam, Netherlands.ORCID 0000-0002-5929-2269
Tsung Wai KanDepartment of Biochemistry, Erasmus MC University Medical Center Rotterdam, PO Box 2040, 3000 CA Rotterdam, Netherlands.
Elisa de CrignisDepartment of Biochemistry, Erasmus MC University Medical Center Rotterdam, PO Box 2040, 3000 CA Rotterdam, Netherlands.
Miroslav SulcInstitute of Microbiology of the Czech Academy of Sciences, Videnska 1083, CZ 14220 Prague 4, Czech Republic.
Joyce H G LebbinkDepartments of Molecular Genetics and Radiation Oncology, Erasmus University Medical Center, PO Box 2040, 3000 CA Rotterdam, Netherlands.
Casper RokxDepartment of Internal Medicine, Section of Infectious Diseases, Erasmus University Medical Center, PO Box 2040, 3000 CA, Rotterdam, Netherlands.
Annelies VerbonDepartment of Internal Medicine, Section of Infectious Diseases, Erasmus University Medical Center, PO Box 2040, 3000 CA, Rotterdam, Netherlands.
Wilfred van IjckenErasmus MC Genomics Core Facility, Department of Cell Biology, Erasmus University Medical Center, PO Box 2040, 3000 CA, Rotterdam, Netherlands.ORCID 0000-0002-0421-8301
Peter D KatsikisDepartment of Immunology, Erasmus MC University Medical Center Rotterdam, PO Box 2040, 3000 CA Rotterdam, Netherlands.ORCID 0000-0001-7690-5218
Robert-Jan PalstraDepartment of Biochemistry, Erasmus MC University Medical Center Rotterdam, PO Box 2040, 3000 CA Rotterdam, Netherlands.ORCID 0000-0003-4600-2303
Vladimir HavlicekInstitute of Microbiology of the Czech Academy of Sciences, Videnska 1083, CZ 14220 Prague 4, Czech Republic.ORCID 0000-0002-8614-7059
Sybren de HoogWesterdijk Fungal Biodiversity Institute, Utrecht, Netherlands.
Tokameh MahmoudiDepartment of Biochemistry, Erasmus MC University Medical Center Rotterdam, PO Box 2040, 3000 CA Rotterdam, Netherlands.ORCID 0000-0002-2060-9353
Erasmus MC · NLCzech Academy of Sciences · CZRadboud University Nijmegen · NLGuiyang Medical University · CNMashhad University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A leading pharmacological strategy toward HIV cure requires "shock" or activation of HIV gene expression in latently infected cells with latency reversal agents (LRAs) followed by their subsequent clearance. In a screen for novel LRAs, we used fungal secondary metabolites as a source of bioactive molecules. Using orthogonal mass spectrometry (MS) coupled to latency reversal bioassays, we identified gliotoxin (GTX) as a novel LRA. GTX significantly induced HIV-1 gene expression in latent ex vivo infected primary cells and in CD4

Indexed as

GliotoxinHIV-1HIV InfectionsHeLa CellsHumansPositive Transcriptional Elongation Factor BRibonucleoproteinsRibonucleoproteins, Small NuclearRNA-Binding ProteinsTranscription FactorsGliotoxinLarp7 protein, humanPositive Transcriptional Elongation Factor BRibonucleoproteinsRibonucleoproteins, Small NuclearRNA-Binding ProteinsTranscription Factors

Identifiers

PMID32851167
PMCPMC7423394
OpenAlexW3048917395

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.